Discrimination of patients with different serological evolution of HIV and co‐infection with HCV using metabolic fingerprinting based on Fourier transform infrared

Human immunodeficiency virus (HIV) is a retrovirus that weakens the immune system and permits opportunistic diseases such as hepatitis C (HCV) to enter the body. These diseases induce metabolic disorders in the patients and it is therefore logical to approach them from a holistic, functional perspective, studying the metabolome comprehensively to identify metabolic signatures associated with certain disease states. The metabolomics strategy here proposed involves metabolic fingerprinting using Fourier transform infrared spectroscopy and chemometric tools on 72 plasma samples (subdivided into 63 training and 9 test samples) to differentiate between healthy subjects and patients with different disease stages. Several options, relating to the variable selection method used in linear discriminant analysis and the number of categories being considered, were explored to optimize discrimination ability. A total of 18 bands enabled differentiation between control subjects, HIV patients and the group that encompassed patients with acquired immune deficiency syndrome (AIDS), AIDS/HCV and HIV/HCV, providing overall classification and internal prediction rates of 97.67% and 93.65%, respectively. Only 9 bands were required to further discriminate between AIDS, AIDS/HCV and HIV/HCV, with 99.20% (training) and 89.66% (cross-validation) correct classifications. The simplicity and effectiveness of the classification methodology proposed was reinforced by the satisfactory results obtained in external prediction.

[1]  F. Martin,et al.  Vibrational biospectroscopy coupled with multivariate analysis extracts potentially diagnostic features in blood plasma/serum of ovarian cancer patients , 2014, Journal of biophotonics.

[2]  David I. Ellis,et al.  Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. , 2006, The Analyst.

[3]  B. Lau,et al.  C-reactive protein is a marker for human immunodeficiency virus disease progression. , 2006, Archives of internal medicine.

[4]  S. Crystal,et al.  HIV infection and the risk of diabetes mellitus , 2008, AIDS.

[5]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[6]  W. K. Henry,et al.  Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Manku,et al.  Plasma fatty acid levels in patients with acquired immune deficiency syndrome and in controls. , 1989, Prostaglandins, leukotrienes, and essential fatty acids.

[8]  A. Sakudo,et al.  Spectroscopic characterization of human immunodeficiency virus type-1-infected plasma by principal component analysis and soft independent modeling of class analogy of visible and near-infrared spectra. , 2009, Molecular medicine reports.

[9]  Sarah Cohen,et al.  How viruses access the nucleus. , 2011, Biochimica et biophysica acta.

[10]  Francis L Martin,et al.  Extracting biological information with computational analysis of Fourier-transform infrared (FTIR) biospectroscopy datasets: current practices to future perspectives. , 2012, The Analyst.

[11]  F. Martin,et al.  Vibrational spectroscopy of biofluids for disease screening or diagnosis: translation from the laboratory to a clinical setting , 2014, Journal of biophotonics.

[12]  A. Sakudo,et al.  A Novel Diagnostic Method for Human Immunodeficiency Virus Type‐1 in Plasma by Near‐Infrared Spectroscopy , 2005, Microbiology and immunology.

[13]  E. Operskalski,et al.  HIV/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies , 2011, Current HIV/AIDS reports.

[14]  C. Pizarro,et al.  Vinegar classification based on feature extraction and selection from headspace solid-phase microextraction/gas chromatography volatile analyses: a feasibility study. , 2008, Analytica chimica acta.

[15]  C. Lewis,et al.  Association of HIV Infection and HIV/HCV Coinfection With C-Reactive Protein Levels: The Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Study , 2008, Journal of acquired immune deficiency syndromes.

[16]  M. Dubé Disorders of glucose metabolism in patients infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  Akikazu Sakudo,et al.  Diagnosis of HIV-1 infection by near-infrared spectroscopy: analysis using molecular clones of various HIV-1 subtypes. , 2012, Clinica chimica acta; international journal of clinical chemistry.

[18]  E. Overton,et al.  Metabolic Consequences of HIV: Pathogenic Insights , 2014, Current HIV/AIDS Reports.

[19]  B. Bistrian,et al.  Metabolic syndrome and serum fatty acid patterns in serum phospholipids in hypertriglyceridemic persons with human immunodeficiency virus. , 2009, The American journal of clinical nutrition.

[20]  J. Carton,et al.  Hepatitis C virus in patients with HIV infection and lipodystrophy. , 2003, Journal of acquired immune deficiency syndromes.

[21]  Monica Casale,et al.  Stepwise orthogonalization of predictors in classification and regression techniques: An “old” technique revisited , 2007 .

[22]  C. Sergeant,et al.  Fatty acids and plasma antioxidants in HIV-positive patients: correlation with nutritional and immunological status. , 1995, Clinical biochemistry.

[23]  W. Witkiewicz,et al.  Metabolic syndrome in HIV-positive patients , 2015 .

[24]  K. Feingold,et al.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. , 1992, The Journal of clinical endocrinology and metabolism.

[25]  M. Lagunoff,et al.  Viral activation of cellular metabolism. , 2015, Virology.

[26]  David I. Ellis,et al.  Metabolomics: Current analytical platforms and methodologies , 2005 .

[27]  M. Ticchioni,et al.  The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review , 2012, Virology Journal.

[28]  Debra Meyer,et al.  Mid-ATR-FTIR spectroscopic profiling of HIV/AIDS sera for novel systems diagnostics in global health. , 2014, Omics : a journal of integrative biology.

[29]  Susan Morgello,et al.  Plasma metabolomics identifies lipid abnormalities linked to markers of inflammation, microbial translocation, and hepatic function in HIV patients receiving protease inhibitors , 2013, BMC Infectious Diseases.

[30]  H. Doerr,et al.  Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection , 1996, Journal of medical virology.

[32]  Roman Kaliszan,et al.  Metabolomics for laboratory diagnostics. , 2015, Journal of pharmaceutical and biomedical analysis.

[33]  A. Balasubramanyam,et al.  Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management , 2012, Endocrine.